Novavax WKN: A2PKMZ ISIN: US6700024010 Kürzel: NVAX Forum: Aktien Thema: Hauptdiskussion

Ich bin sehr optimistisch. Der Grund ist, dass Longie nicht da ist. Immer wenn er auftaucht, fällt der Preis stark. Jetzt, wo er fehlt, werden wir einen Shortsqueez sehen. $1000 🤩🤩🤩🤩.

Während Novavax um die BLA kämpft und Insolvenz vermeiden möchte, träumen einige von einem Aktienkurs über 1000 Dollar! Wahnsinn, wie unendlich Träume sein können!

If mRNA vaccines (such as those from Pfizer and Moderna) were banned, and only Novavax remained with its COVID and combination vaccine (COVID + flu), the market landscape would change dramatically. Market Situation: The global population is around 8 billion. Even if only 1 billion people received a combination vaccine annually, and the price per dose ranged between $30 and $50, the net profit per dose (after production costs) could be approximately $10 to $15. This means: An annual net profit of $10 to $15 billion could be achievable for Novavax. Impact on Stock Price: With an annual profit of, say, $15 billion and approximately 130 million outstanding shares, the earnings per share (EPS) would be around $115. Based on typical price-to-earnings (P/E) ratios: At a P/E of 10, the share price could be around $1,150 At a P/E of 20, it could reach over $2,300 Conclusion: If Novavax were to monopolize the vaccine market, the stock could theoretically exceed $1,000 per share. This assumes no major government price controls and no fast-moving competitors entering the space.

If mRNA vaccines (such as those from Pfizer and Moderna) were banned, and only Novavax remained with its COVID and combination vaccine (COVID + flu), the market landscape would change dramatically. Market Situation: The global population is around 8 billion. Even if only 1 billion people received a combination vaccine annually, and the price per dose ranged between $30 and $50, the net profit per dose (after production costs) could be approximately $10 to $15. This means: An annual net profit of $10 to $15 billion could be achievable for Novavax. Impact on Stock Price: With an annual profit of, say, $15 billion and approximately 130 million outstanding shares, the earnings per share (EPS) would be around $115. Based on typical price-to-earnings (P/E) ratios: At a P/E of 10, the share price could be around $1,150 At a P/E of 20, it could reach over $2,300 Conclusion: If Novavax were to monopolize the vaccine market, the stock could theoretically exceed $1,000 per share. This assumes no major government price controls and no fast-moving competitors entering the space.